Among patients with pancreatic cancer, 90% carry a KRAS mutation, which is considered a driver gene for pancreatic cancer progression, and 50–80% have inactivating mutations in TP53, CDKN2A, and SMAD4 [2]. This evidence concerns the gene CDKN2A and familial pancreatic carcinoma.